Daewoong proved its sales power once again as it solidified its top position in the new oral anticoagulant (NOAC) market with Daiichi Sankyo's Lixiana.
|Non-vitamin K antagonist oral anticoagulants (clockwise from top left): Bayer’s Xarelto, Daichi Sankyo’s Lixiana, Boehringer Ingelheim's Pradaxa, and BMS’ Eliquis|
Notably, the company has managed to stay on top, despite Bayer resuming the sale of Xarelto, which had been the top seller in the NOAC market, after recovering from supply cuts.
According to UBIST data, Lixiana outpatient prescriptions recorded 5.1 billion won ($4.2 million) in August, up 72.2 percent from the same period of last year. The amount was 0.3 percent lower than the sales in July, but the drug still kept a safe lead compared to runner-up Xarelto's 4 billion won.
Xarelto gave the top position in the NOAC market to Lixiana due to a supply problem in the first half of this year. However, the company expected to retake first place after resolving its supply in the second half.
Despite Bayer's ambition, the company did not see its sales recover in both July and August, and Lixiana further managed to widen the sales gap from 736 million won in July to 1.1 billion won in August.
Bayer managed to slightly increase the gap between Xarelto and BMS' Eliquis as the latter recorded a more significant drop in performance. BMS managed to record sales of 310 million won for Eliquis, an 11.4 percent drop from the previous month.
Such decrease in sales resulted in the gap with Xarelto to widen from 310 million won in July to 387 million won in August.
Bohringer Ingelheim's Pradaxa, which recorded relatively small revenue, showed a more stable sale performance than Xarelto and Eliquis
Pradaxa's August earnings sales were 1.4 billion won, down 5.3 percent from the previous month.
<© Korea Biomedical Review, All rights reserved.>